Are you interested in licensing or collaborating on a new immunotherapy method to target solid tumors? The National Cancer Institute’s distinguished inventor, Dr. John Schiller, will be discussing this invention and fielding questions on December 14, 2022.

This technology involves the injection of cytomegalovirus – (CMV) derived T cell minimal peptide epitopes into a solid tumor. This disrupts the tumor microenvironment and allows CD4+ and CD8+ T cells to kill the tumor cells and the generation of T cells to tumor-restricted antigens. The tumor antigen-agnostic nature of this approach makes it applicable across a broad range of solid tumors, regardless of origin.

Results show that CMV-derived peptide epitopes, delivered intratumorally into mice with chronic mouse CMV infections, act as cytotoxic and immunotherapeutic agents to promote immediate tumor control and long-term antitumor immunity. This technology can be used as a stand-alone therapy.

The competitive advantages of this technology include:

• No requirement to characterize tumor-associated antigens.
• Tumor agnostic method applicable across a broad range of solid tumors.
• No requirement for the laborious process of clonal T-cell expansion versus CAR-T cell-based immunotherapies.
• Not dependent on immune checkpoint blockade.
• Immediate treatment following diagnosis.
• “Off the shelf” capabilities provide easier scale-up and lower cost of manufacturing.

This free webinar will take place on December 14, 2022 from 11 AM to 12PM ET. It is a wonderful opportunity for business development and drug development professional, investors, entrepreneurs, and biotech, pharma, and academia researchers to hear from the inventors and ask questions in order to assess the co-development and/or licensing opportunity.

To read further about this technology, you can view the abstract. 

If this is not the right opportunity for you, take a look at over 1,500 other technologies the NIH is offering for licensing or collaboration.